Semin Arthritis Rheu: Diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis

The study was designed to assess the impact of disease-improved anti-rheumatoid drugs on diabetes risk in patients withrwithout diabetessearch edited and manually searched the pubMed, EMBASE and Cochrane libraries' electronic databases, as well as meeting minutes, respectively, for studies published by October 2019Include cohort studies or case-control studies that assess the association between diabetes and anti-rheumatic drugs in RA patientsAccording to I2, the data are summarized using a meta-analysis of fixed or random effects, and the summary risk ratio (HRs) and its 95% confidence interval (CIs) are summarized statisticsincluded a total of 15 studies, including 552,019 CASES OF RA (11 OXYCHLOROQUINE, METHOTREXATE 7, TUMOR NECROSIS INHIBITORS (TNFI) 6, GLUCOCORTICOIDS 8)In summary analysis, hydroxychloroquine (meta-HR 0.61, 95% CI 0.56-0.66), methotrexate (meta-HR 0.81, 95% CI 0.75-0.87) and TNFi (meta) were used -HR 0.63, 95% CI 0.55-0.71) was associated with a reduced risk of diabetes, while glucocorticoids increased the risk of diabetes in dose-dependent manner (any dose: meta-HR 1.46, 95% CI 1.39-1.53?? : Pernison dragon 10 mg/day or equivalent dose: meta-HR 1.30, 95% CI 1.13-1.51; pernitson dragon s 10 mg/day or equivalent dose: meta-HR 2.25, 95% CI 1.88-2.70)in RA patients, hydroxychloroquine, methotrexate and TNFi were associated with a reduced risk of diabetes, while glucocorticoids were associated with an increased risk of diabetesThese important findings contribute to clinical decision-making of RA treatmentLarge-scale, forward-looking and well-designed studies are required for RA patients with a high risk of diabetes